| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
|
J Chronic Dis
|
1987
|
174.79
|
|
2
|
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
|
N Engl J Med
|
2008
|
13.06
|
|
3
|
Improved survival in multiple myeloma and the impact of novel therapies.
|
Blood
|
2007
|
12.70
|
|
4
|
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
|
Lancet
|
2007
|
7.23
|
|
5
|
Multiple myeloma.
|
Blood
|
2008
|
5.88
|
|
6
|
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
|
Lancet
|
2010
|
5.59
|
|
7
|
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
|
Lancet
|
2006
|
5.07
|
|
8
|
Clinical and biologic implications of recurrent genomic aberrations in myeloma.
|
Blood
|
2003
|
4.67
|
|
9
|
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
|
Blood
|
2010
|
4.52
|
|
10
|
Recent major improvement in long-term survival of younger patients with multiple myeloma.
|
Blood
|
2007
|
4.08
|
|
11
|
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
|
J Clin Oncol
|
2010
|
4.02
|
|
12
|
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
|
J Clin Oncol
|
2012
|
3.93
|
|
13
|
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
|
Blood
|
2012
|
3.44
|
|
14
|
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
|
Blood
|
2010
|
2.84
|
|
15
|
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
|
Blood
|
2008
|
2.68
|
|
16
|
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
|
J Clin Oncol
|
2009
|
2.49
|
|
17
|
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
|
Blood
|
2012
|
2.42
|
|
18
|
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.
|
Blood
|
2011
|
2.37
|
|
19
|
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
|
Blood
|
2010
|
2.33
|
|
20
|
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
|
N Engl J Med
|
2016
|
2.32
|
|
21
|
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
|
J Clin Oncol
|
2010
|
2.25
|
|
22
|
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
|
Blood
|
2012
|
2.07
|
|
23
|
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).
|
Leukemia
|
2013
|
2.04
|
|
24
|
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
|
J Clin Oncol
|
2010
|
1.81
|
|
25
|
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
|
Blood
|
2010
|
1.79
|
|
26
|
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
|
Blood
|
2011
|
1.69
|
|
27
|
Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.
|
J Clin Oncol
|
2011
|
1.60
|
|
28
|
How I treat multiple myeloma in younger patients.
|
Blood
|
2009
|
1.48
|
|
29
|
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
|
Blood
|
2011
|
1.32
|
|
30
|
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
|
Eur J Haematol
|
2010
|
1.30
|
|
31
|
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.
|
Cancer
|
2011
|
1.18
|
|
32
|
Fluorescence in situ hybridization: uses and limitations.
|
Semin Hematol
|
2000
|
1.16
|
|
33
|
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
|
Blood
|
2014
|
0.89
|
|
34
|
Initial treatment of nontransplant patients with multiple myeloma.
|
Semin Oncol
|
2013
|
0.78
|
|
35
|
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
|
N Engl J Med
|
2017
|
0.75
|